Clinical trial
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects…
NCT00056823 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00056823 |
|---|---|
| Title | Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD) |
| Official title | A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination With Verteporfin (Visudyne(R)) Photodynamic Therapy in Subjects With Neovascular Age Related Macular Degeneration |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Age-Related Maculopathy |
| Intervention type | Drug |
| Interventions | rhuFab V2 (ranibizumab) |
| Enrollment | 168 |
| Start date | Mar 1, 2003 |
| Completion | Dec 1, 2005 |
| First posted | Mar 26, 2003 |
| Last update posted | Jun 21, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: